FIELD: chemical-pharmaceutical industry.
SUBSTANCE: invention relates to novel quinazolin-4(3H)-one derivatives of general formula
,
where R1=H or CH3; R2=H, CH3, Cl or Br; R3=H or Br; R4=H or CH3, which have inhibitory activity against sodium-hydrogen exchanger of the first isoform. During in vitro experiments on rabbit platelets the compounds demonstrate inhibitory concentration of IC50 in the range of 1 × 10-8 to 1 × 10-12 mol/l and significantly exceed the zoniporide, comparator drug.
EFFECT: new quinazoline-4(3H)-one derivatives can be used in the development of effective and safe neuro- and cardioprotective drugs that implement their therapeutic benefits by affecting sodium-hydrogen metabolism.
1 cl, 2 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MEDICATION, INHIBITING Na+/H+-EXCHANGE, AND HALOGENIDES OF 1-DIALKYLAMINOETHYL-3-[SUBSTITUTED(DISUBSTITUTED)PHENACYL]-2-AMINOBENZIMIDAZOLIUM | 2013 |
|
RU2518741C1 |
| METHOD, INHIBITING Na+/H+-EXCHANGE, AND DIHYDROCHLORIDE OF 2-(3,4-METHYLENEDIOXYPHENYL)-9-MORPHOLINOETHYLIMIDAZO[1,2-a]BENZIMIDAZOLE | 2013 |
|
RU2518740C1 |
| AGENT HAVING CARDIOPROTECTIVE ACTION AND 1,3-DISUBSTITUTED 2-AMINOBENZIMIDAZOLIUM HALIDES | 2013 |
|
RU2526902C1 |
| DERIVATIVES OF QUINAZOLINE-4 (3H)-ONE, WITH NEURO- AND CARDIOPROTECTIVE ACTIVITY | 2016 |
|
RU2622638C1 |
| METHOD OF PRODUCING N-((HYDROXYAMINO)-OXOALKYL)-2-(QUINAZOLIN-4-YLAMINO)-BENZAMIDES | 2019 |
|
RU2722694C1 |
| HYDROXAMIC ACIDS, 4-AMINOQUINAZOLINE DERIVATIVES WITH ANTITUMOR ACTIVITY | 2022 |
|
RU2802463C1 |
| DERIVATIVES OF 1-(3,5-DI-TERT-BUTYL-4-HYDROXYBENZYL)ISATIN HAVING ANTIAGGREGATORY ACTIVITY | 2023 |
|
RU2822271C1 |
| NEW CHLORINE e DERIVATIVES, CONTAINING FRAGMENTS OF GALACTOSE | 2019 |
|
RU2706698C1 |
| 1-SUBSTITUTED-3-{[2-(3,5-DI-TRET-4-HYDROXYPHENYL)-2-OXOETHYL]}-2AMINOBENZIMIDAZOLIUM BROMIDES WITH ANTIPLATELET AND ANTIOXIDANT PROPERTIES | 2016 |
|
RU2623439C1 |
| 2-(5-NITRONYLFURAN-2-YL)-5-METHYL-6-NITRO-1,2,4-TRIAZOLO[1,5-A]PYRIMIDIN-7(4N)-ONE AND SALTS THEREOF | 2018 |
|
RU2716715C2 |
